Fiscal 2020

## Supplementary Materials

HOGY MEDICAL Co., Ltd.
April, 142021

## Table of Contents

## Consolidated Basis

Fiscal 2020 Statements of Income ..... 1 P
Fiscal 2020 Statements of Income by Half ..... $2 P$
Fiscal 2021 Projected Statements of Income ..... $3 P$
Fiscal 2020 Sales Results by Product Line ..... 4 P
Fiscal 2021 Sales Plan by Product Line ..... 5 P
SG\&A (Actual and Forecast)
Other Income/Expenses (Actual and Forecast) ..... 6 P
Capital Expenditures and Depreciation Expenses ..... 7 P
Balance Sheets (Major Changes) ..... 8 P
Statements of Cash Flows
Non-Consolidated Basis
Fiscal 2020 Statements of Income ..... 9 P
Fiscal 2020 Statements of Income by Half ..... 10 P
Fiscal 2021 Projected Statements of Income ..... 11 P
Total Manufacturing Costs ..... 12 P

## (Notes Concerning Forward-Looking Statements)

Projections throughout these materials are provided as a reference for investors. They are based on estimates and forecasts, and shall not be regarded as pledges or guarantees. They shall be used on the full acknowledgment that actual results may naturally differ from projections.

Fiscal 2020 Statements of Income (Consolidated)

| First Quarter Results $\quad$ \# |  |  |  |  | millions, rounded down |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | June 2020 <br> First Quarter Results |  | June 2019First Quarter Results |  | Year-on-Year Comparison |  |
|  | Amount | \% of total | Amount | \% of total | Amount | \% |
| Net sales | 8,376 | 100.0 | 9,038 | 100.0 | $\triangle 661$ | 92.7 |
| Cost of Sales | 4,874 | 58.2 | 5,243 | 58.0 | $\triangle 368$ | 93.0 |
| Gross profit | 3,502 | 41.8 | 3,794 | 42.0 | $\triangle 292$ | 92.3 |
| SG\&A expenses | 2,358 | 28.2 | 2,459 | 27.2 | $\triangle 101$ | 95.9 |
| Operating income | 1,143 | 13.7 | 1,335 | 14.8 | $\triangle 191$ | 85.7 |
| Other income | 109 |  | 69 |  | 39 |  |
| Other expenses | 1 |  | 3 |  | $\triangle 1$ |  |
| Ordinary income | 1,251 | 14.9 | 1,401 | 15.5 | $\triangle 149$ | 89.3 |
| Extraordinary income |  |  |  |  | - |  |
| Extraordinary expenses |  |  | 0 |  | $\triangle 0$ |  |
| interests | 1,251 | 14.9 | 1,401 | 15.5 | $\triangle 149$ | 89.3 |
| Corporation tax,inhabitants taxes, etc. | 352 |  | 422 |  | $\triangle 70$ |  |
| (Tax burden) | 28.1\% |  | 30.2\% |  |  |  |
| Minority interests | $\triangle 8$ |  | $\triangle 7$ |  | $\triangle 1$ |  |
| Profit attributable to owners of parent | 908 | 10.8 | 986 | 10.9 | $\triangle 78$ | 92.1 |


| EPS (total shares) | $¥ 27.78$ |  |
| :--- | ---: | ---: |
| EPS (minus treasury shares) | $¥ 30.04$ | $¥ 30.17$ |
| Number of shares outstanding <br> Average number of shares outstanding <br> (after deducting treasury shares) | $32,682,310$ | $32,682,310$ |



|  | Sept. 2020 <br> Interim Results |  | Sept. 2019 <br> Interim Results |  | Year-on-Year Comparison |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | Amount | \% of total | Amount | \% of total | Amount | \% |
| Net sales | 17,734 | 100.0 | 18,380 | 100.0 | $\triangle 645$ | 96.5 |
| Cost of Sales | 10,374 | 58.5 | 10,810 | 58.8 | $\triangle 436$ | 96.0 |
| Gross profit | 7,360 | 41.5 | 7,570 | 41.2 | $\triangle 209$ | 97.2 |
| SG\&A expenses | 4,689 | 26.4 | 4,973 | 27.1 | $\triangle 284$ | 94.3 |
| Operating income | 2,671 | 15.1 | 2,596 | 14.1 | 74 | 102.9 |
| Other income | 138 |  | 131 |  | 6 |  |
| Other expenses | 3 |  | 3 |  | $\triangle 0$ |  |
| Ordinary income | 2,806 | 15.8 | 2,724 | 14.8 | 81 | 103.0 |
| Extraordinary income | 1,028 |  | 1,943 |  | $\triangle 914$ |  |
| Extraordinary expenses | 1 |  | 1 |  | $\triangle 0$ |  |
| Income before income taxes and minority | 3,833 | 21.6 | 4,665 | 25.4 | $\triangle 832$ | 82.2 |
| Corporation tax, inhabitants taxes, etc. | 1,068 |  | 1,415 |  | $\triangle 347$ |  |
| (Tax burden) | 27.9\% |  | 30.3\% |  |  |  |
| Minority interests | $\triangle 11$ |  | $\triangle 15$ |  | 4 |  |
| Profit attributable to owners of parent | 2,776 | 15.7 | 3,265 | 17.8 | $\triangle 489$ | 85.0 |
| EPS (total shares) | ¥84.94 |  | ¥99.91 |  |  |  |
| EPS (minus treasury shares) | $¥ 91.84$ |  | $¥ 108.14$ |  |  |  |
| Number of shares outstanding | 32,682,310 |  | 2,682,310 |  |  |  |
| Average number of shares outstanding (after deducting treasury shares) | 30,228,126 |  | 0,196,594 |  |  |  |


| Third Quarter Results (Cumulative) |  |  |  |  | $\neq$ millions, rounded down |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | Dec. 2020 <br> Third Quarter Results |  | Dec. 2019 <br> Third Quarter Results |  | Year-on-Year Comparison |  |
|  | Amount | \% of total | Amount | \% of total | Amount | \% |
| Net sales | 27,696 | 100.0 | 28,060 | 100.0 | $\triangle 363$ | 98.7 |
| Cost of Sales | 16,070 | 58.0 | 16,430 | 58.6 | $\triangle 360$ | 97.8 |
| Gross profit | 11,626 | 42.0 | 11,629 | 41.4 | $\triangle 3$ | 100.0 |
| SG\&A expenses | 7,118 | 25.7 | 7,525 | 26.8 | $\triangle 407$ | 94.6 |
| Operating income | 4,508 | 16.3 | 4,104 | 14.6 | 403 | 109.8 |
| Other income | 417 |  | 436 |  | $\triangle 19$ |  |
| Other expenses | 6 |  | 21 |  | $\triangle 14$ |  |
| Ordinary income | 4,919 | 17.8 | 4,520 | 16.1 | 399 | 108.8 |
| Extraordinary income | 1,028 |  | 1,943 |  | $\triangle 914$ |  |
| Extraordinary expenses | 3 |  | 1 |  | 1 |  |
| Income before income taxes and minority | 5,945 | 21.5 | 6,461 | 23.0 | $\triangle 516$ | 92.0 |
| Corporation tax,inhabitants taxes, etc. | 1,667 |  | 1,911 |  | $\triangle 244$ |  |
| (Tax burden) | 28.0\% |  | 29.6\% |  |  |  |
| Minority interests | $\triangle 18$ |  | $\triangle 25$ |  | 7 |  |
| Profit attributable to owners of parent | 4,296 | 15.5 | 4,576 | 16.3 | $\triangle 279$ | 93.9 |
| EPS (total shares) | ¥131.45 |  | ¥140.01 |  |  |  |
| EPS (minus treasury shares) | $¥ 142.11$ |  | $¥ 151.52$ |  |  |  |
| Number of shares outstanding | 32,682,310 |  | 32,682,310 |  |  |  |
| Average number of shares outstanding |  |  |  |  |  |  |
| (after deducting treasury shares) | 30,232,009 |  | 30,200,684 |  |  |  |


| Full-year Results | $¥$ millions, rounded down |  |  |  |  |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | Fiscal 2020 Results |  | Fiscal 2019 Results |  | Year-on-Year Comparison |  | Fiscal 2020 <br> Revised Plan |  | Revised Plan Comparison |  |
|  | Amount | \% of total | Amount | \% of total | Amount | \% | Amount | \% of tota | Amount | \% |
| Net sales | 36,504 | 100.0 | 37,232 | 100.0 | $\triangle 728$ | 98.0 | 36,310 | 100.0 | 194 | 100.5 |
| Cost of Sales | 21,177 | 58.0 | 21,798 | 58.5 | $\triangle 620$ | 97.2 | 21,010 | 57.9 | 167 | 100.8 |
| Gross profit | 15,326 | 42.0 | 15,434 | 41.5 | $\triangle 107$ | 99.3 | 15,300 | 42.1 | 26 | 100.2 |
| SG\&A expenses | 9,694 | 26.6 | 10,126 | 27.2 | $\triangle 432$ | 95.7 | 9,810 | 27.0 | $\triangle 115$ | 98.8 |
| Operating income | 5,632 | 15.4 | 5,307 | 14.3 | 324 | 106.1 | 5,490 | 15.1 | 142 | 102.6 |
| Other income | 421 |  | 505 |  | $\triangle 83$ |  | 460 |  | $\triangle 38$ |  |
| Other expenses | 65 |  | 22 |  | 43 |  | 20 |  | 45 |  |
| Ordinary income | 5,988 | 16.4 | 5,791 | 15.6 | 197 | 103.4 | 5,930 | 16.3 | 58 | 101.0 |
| Extraordinary income | 1,030 |  | 1,943 |  | $\triangle 913$ |  | 1,030 |  | 0 |  |
| Extraordinary expenses | 28 |  | 9 |  | 19 |  | 10 |  | 18 |  |
| Income before income taxes and minority | 6,989 | 19.1 | 7,725 | 20.7 | $\triangle 735$ | 90.5 | 6,950 | 19.1 | 39 | 100.6 |
| Corporation tax,inhabitants taxes, etc. | 2,060 |  | 2,235 |  | $\triangle 175$ |  | 2,000 |  | 60 |  |
| (Tax burden) | 29.5\% |  | 28.9\% |  |  |  | 28.8\% |  |  |  |
| Minority interests | $\triangle 30$ |  | $\triangle 40$ |  | 10 |  | $\triangle 30$ |  | $\triangle 0$ |  |
| Profit attributable to owners of parent | 4,959 | 13.6 | 5,529 | 14.9 | $\triangle 570$ | 89.7 | 4,980 | 13.7 | $\triangle 20$ | 99.6 |
| EPS (total shares) | ¥151.73 |  | ¥169.19 |  |  |  | $¥ 152.38$ |  |  |  |
| EPS (minus treasury shares) | $¥ 164.03$ |  | $¥ 183.07$ |  |  |  | $¥ 164.73$ |  |  |  |
| Number of shares outstanding | 32,682,310 |  | 32,682,310 |  |  |  | 32,682,310 |  |  |  |
| Average number of shares outstanding (after deducting treasury shares) | 30,231,715 |  | 30,204,965 |  |  |  | 30,231,715 |  |  |  |

Fiscal 2020 Statements of Income by Quarter (Consolidated)

|  | $\begin{gathered} \text { First } \\ \text { Quarter } \end{gathered}$ | Second <br> Quarter | $\begin{gathered} \text { Third } \\ \text { Quarter } \end{gathered}$ | Fourth Quarter |
| :---: | :---: | :---: | :---: | :---: |
| Net sales | 8,376 | 9,358 | 9,961 | 8,807 |
| Cost of Sales | 4,874 | 5,499 | 5,695 | 5,107 |
| Gross profit | 3,502 | 3,858 | 4,265 | 3,700 |
| SG\&A expenses | 2,358 | 2,331 | 2,429 | 2,576 |
| Operating income | 1,143 | 1,527 | 1,836 | 1,124 |
| Other income | 109 | 29 | 279 | 4 |
| Other expenses | 1 | 1 | 2 | 59 |
| Ordinary income | 1,251 | 1,554 | 2,113 | 1,068 |
| Extraordinary income |  | 1,028 |  | 1 |
| Extraordinary expenses |  | 1 | 1 | 25 |
| Income before income taxes and minority | 1,251 | 2,581 | 2,111 | 1,044 |
| Corporation tax,inhabitants taxes, etc. | 352 | 716 | 598 | 393 |
| (Tax burden) | 28.1\% | 27.7\% | 28.3\% | 37.7\% |
| Minority interests | $\triangle 8$ | $\triangle 2$ | $\triangle 6$ | $\triangle 11$ |
| Profit attributable to owners of parent\| | 908 | 1,868 | 1,520 | 662 |

## Fiscal 2019 Results

|  | First Quarter | Second Quarter | Third Quarter | Fourth Quarter |
| :---: | :---: | :---: | :---: | :---: |
| Net sales | 9,038 | 9,342 | 9,679 | 9,172 |
| Cost of Sales | 5,243 | 5,566 | 5,620 | 5,367 |
| Gross profit | 3,794 | 3,775 | 4,059 | 3,804 |
| SG\&A expenses | 2,459 | 2,514 | 2,551 | 2,601 |
| Operating income | 1,335 | 1,261 | 1,507 | 1,203 |
| Other income | 69 | 61 | 305 | 68 |
| Other expenses | 3 | 0 | 17 | 1 |
| Ordinary income | 1,401 | 1,322 | 1,795 | 1,271 |
| Extraordinary income |  | 1,943 | 0 | 0 |
| Extraordinary expenses | 0 | 1 | 0 | 7 |
| Income before income taxes and minority | 1,401 | 3,264 | 1,795 | 1,263 |
| Corporation tax,inhabitants taxes, etc. | 422 | 993 | 495 | 324 |
| (Tax burden) | 30.2\% | 30.4\% | 27.6\% | 25.7\% |
| Minority interests | $\triangle 7$ | $\triangle 8$ | $\triangle 10$ | $\triangle 14$ |
| Profit attributable to owners of parent | 986 | 2,279 | 1,310 | 953 |

## Change(Amount)

|  | First Quarter | Second Quarter | Third Quarter | Fourth Quarter |
| :---: | :---: | :---: | :---: | :---: |
| Net sales | $\triangle 661$ | 15 | 282 | $\triangle 364$ |
| Cost of Sales | $\triangle 368$ | $\triangle 67$ | 75 | $\triangle 260$ |
| Gross profit | $\triangle 292$ | 82 | 206 | $\triangle 104$ |
| SG\&A expenses | $\triangle 101$ | $\triangle 183$ | $\triangle 122$ | $\triangle 24$ |
| Operating income | $\triangle 191$ | 265 | 328 | $\triangle 79$ |
| Other income | 39 | $\triangle 32$ | $\triangle 26$ | $\triangle 64$ |
| Other expenses | $\triangle 1$ | 1 | $\triangle 14$ | 58 |
| Ordinary income | $\triangle 149$ | 231 | 317 | $\triangle 202$ |
| Extraordinary income |  | $\triangle 914$ | $\triangle 0$ | 1 |
| Extraordinary expenses | $\triangle 0$ | $\triangle 0$ | 1 | 18 |
| Income before income taxes and minority | $\triangle 149$ | $\triangle 682$ | 315 | $\triangle 219$ |
| Corporation tax,inhabitants taxes, etc. | $\triangle 70$ | $\triangle 276$ | 103 | 68 |
| (Tax burden) |  |  |  |  |
| Minority interests | $\triangle 1$ | 5 | 3 | 2 |
| Profit attributable to owners of parent | $\triangle 78$ | $\triangle 411$ | 209 | $\triangle 290$ |


| First Half | Third Quarter (Cumulative) | Full-year |
| :---: | :---: | :---: |
| $\triangle 645$ | $\triangle 363$ | $\triangle 728$ |
| $\triangle 436$ | $\triangle 360$ | $\triangle 620$ |
| $\triangle 209$ | $\triangle 3$ | $\triangle 107$ |
| $\triangle 284$ | $\triangle 407$ | $\triangle 432$ |
| 74 | 403 | 324 |
| 6 | $\triangle 19$ | $\triangle 83$ |
| $\triangle 0$ | $\triangle 14$ | 43 |
| 81 | 399 | 197 |
| $\triangle 914$ | $\triangle 914$ | $\triangle 913$ |
| $\triangle 0$ | 1 | 19 |
| $\triangle 832$ | $\triangle 516$ | $\triangle 735$ |
| $\triangle 347$ | $\triangle 244$ | $\triangle 175$ |
|  |  |  |
| 4 | 7 | 10 |
| $\triangle 489$ | $\triangle 279$ | $\triangle 570$ |

Change(\%)

|  | First <br> Quarter | Second <br> Quarter | Third <br> Quarter | Fourth <br> Quarter |
| :--- | ---: | ---: | ---: | ---: |
| Net sales | 92.7 | 100.2 | 102.9 | 96.0 |
| Cost of Sales | 93.0 | 98.8 | 101.3 | 95.2 |
| SG\&A expenses | 92.3 | 102.2 | 105.1 | 97.3 |
| Gross profit | 95.9 | 92.7 | 95.2 | 99.0 |
| Other income | 85.7 | 121.1 | 121.8 | 93.4 |
| Other expenses |  |  |  |  |
| Operating income |  |  |  |  |
| Extraordinary income |  | 89.3 | 117.5 | 117.7 |
| Extraordinary expenses |  |  |  | 84.1 |
| Income before income taxes and minority |  | 89.3 | 79.1 | 117.6 |
| Corporation tax,inhabitants taxes, etc. |  |  |  | 82.6 |
| (Tax burden) |  |  |  |  |
| Minority interests |  |  |  |  |
| Profit attributable to owners of parent | 92.1 | 82.0 | 116.0 | 69.5 |


| First Half | Third Quarter <br> (Cumulative) | Full-year |
| ---: | ---: | ---: |
| 96.5 | 98.7 | 98.0 |
| 96.0 | 97.8 | 97.2 |
| 97.2 | 100.0 | 99.3 |
| 94.3 | 94.6 | 95.7 |
| 102.9 | 109.8 | 106.1 |
|  |  |  |
|  |  |  |
| 103.0 | 108.8 | 103.4 |
|  |  |  |
|  |  |  |
| 82.2 | 92.0 | 90.5 |
|  |  |  |
|  |  |  |
| 85.0 | 93.9 | 89.7 |
|  |  |  |

Fiscal 2020 Breakdown

|  | First Quarter | Second Quarter | Third Quarter | Fourth Quarter |
| :---: | :---: | :---: | :---: | :---: |
| Net sales | 100.0 | 100.0 | 100.0 | 100.0 |
| Cost of Sales | 58.2 | 58.8 | 57.2 | 58.0 |
| Gross profit | 41.8 | 41.2 | 42.8 | 42.0 |
| SG\&A expenses | 28.2 | 24.9 | 24.4 | 29.2 |
| Operating income | 13.7 | 16.3 | 18.4 | 12.8 |
| Other income |  |  |  |  |
| Other expenses |  |  |  |  |
| Ordinary income | 14.9 | 16.6 | 21.2 | 12.1 |
| Extraordinary income |  |  |  |  |
| Extraordinary expenses |  |  |  |  |
| Income before income taxes and minority | 14.9 | 27.6 | 21.2 | 11.9 |
| Corporation tax,inhabitants taxes, etc. |  |  |  |  |
| (Tax burden) |  |  |  |  |
| Minority interests |  |  |  |  |
| Profit attributable to owners of parent\| | 10.8 | 20.0 | 15.3 | 7.5 |


| First Half | Third Quarter <br> (Cumulative) | Full-year |
| ---: | ---: | ---: |
| 100.0 | 100.0 | 100.0 |
| 58.5 | 58.0 | 58.0 |
| 41.5 | 42.0 | 42.0 |
| 26.4 | 25.7 | 26.6 |
| 15.1 | 16.3 | 15.4 |
|  |  |  |
| 15.8 | 17.8 | 16.4 |
|  |  |  |
| 21.6 | 21.5 | 19.1 |
|  |  |  |
|  |  |  |
| 15.7 | 15.5 | 13.6 |

Fiscal 2021 Projected Statements of Income (Consolidated)
Cumulative

|  | $¥$ millions, rounded down,(\%) |  |  |  |
| :--- | ---: | ---: | ---: | ---: |
| Net sales | First Half | \% of total | Full-year | $\%$ of total |
| Operating income | 19,080 | 100.0 | 38,400 | 100.0 |
| Ordinary income | 3,220 | 16.9 | 6,350 | 16.5 |
| Profit attributable to owners of parent | 3,250 | 17.0 | 6,620 | 17.2 |
| EPS (before deducting treasury shares) | 2,350 | 12.3 | 4,720 | 12.3 |
| EPS (minus treasury shares) | $¥ 71.90$ |  | $\neq 144.42$ |  |

Number of shares outstanding $32,682,310$
Shares outstanding at FY2020 year-end 30,122,328
(deducting treasury shares)
Fiscal 2020 Results

| Net sales | 17,734 | 100.0 | 36,504 | 100.0 |
| :--- | ---: | ---: | ---: | ---: |
| Operating income | 2,671 | 15.1 | 5,632 | 15.4 |
| Ordinary income | 2,806 | 15.8 | 5,988 | 16.4 |
| Profit attributable to owners of parent | 2,776 | 15.7 | 4,959 | 13.6 |

Change (Amount and \%)

| Net sales | 1,345 | 107.6 | 1,895 | 105.2 |
| :--- | ---: | ---: | ---: | ---: |
| Operating income | 548 | 120.5 | 717 | 112.7 |
| Ordinary income | 443 | 115.8 | 631 | 110.6 |
| Profit attributable to owners of parent | $\triangle 426$ | 84.7 | $\triangle 239$ | 95.2 |

Fiscal 2020 Sales Results by Product Line (Consolidated)
New products contain Operation management system, EMARO, IC Tracer and containers etc.

| First Half Results $\quad \neq$ |  |  |  |  | $¥$ millions, rounded down |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | Sept. 2020Interim Results |  | Sept. 2019Interim Results |  | Year-on-Year Comparison |  |
|  | Amount | \% of total | Amount | \% of total | Amount | \% |
| Sterilization products | 1,639 | 9.2 | 1,708 | 9.3 | $\triangle 68$ | 96.0 |
| Surgical products | 15,646 | 88.2 | 16,200 | 88.1 | $\triangle 553$ | 96.6 |
| Treatment products | 111 | 0.6 | 92 | 0.5 | 18 | 120.6 |
| Others | 337 | 1.9 | 379 | 2.1 | $\triangle 42$ | 88.7 |
| Total | 17,734 | 100.0 | 18,380 | 100.0 | $\triangle 645$ | 96.5 |
| Itemized surgical products |  |  |  |  |  |  |
| Non-woven products | 4,495 | 25.3 | 4,351 | 23.7 | 143 | 103.3 |
| Other non-woven products | 882 | 5.0 | 592 | 3.2 | 290 | 149.0 |
| Kit products | 10,193 | 57.5 | 11,165 | 60.7 | $\triangle 971$ | 91.3 |
| New products | 75 | 0.4 | 90 | 0.5 | $\triangle 15$ | 82.8 |
| Itemized external sales by subsidiary |  |  |  |  |  |  |
| Non-woven products | 249 |  | 125 |  | 124 |  |
| Other non-woven products | 27 |  | - |  | 27 |  |
| Kit products | 0 |  | - |  | 0 |  |
| Others | 36 |  | 41 |  | $\triangle 4$ |  |


| Third Quarter Results (Cumulative) |  |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | Dec. 2020Third Quarter Results |  | Dec. 2019Third Quarter Results |  | Year-on-Year Comparison |  |
|  | Amount | \% of total | Amount | \% of total | Amount | \% |
| Sterilization products | 2,512 | 9.1 | 2,590 | 9.2 | $\triangle 77$ | 97.0 |
| Surgical products | 24,498 | 88.5 | 24,755 | 88.2 | $\triangle 257$ | 99.0 |
| Treatment products | 169 | 0.6 | 137 | 0.5 | 31 | 123.2 |
| Others | 515 | 1.9 | 576 | 2.1 | $\triangle 60$ | 89.4 |
| Total | 27,696 | 100.0 | 28,060 | 100.0 | $\triangle 363$ | 98.7 |
| Itemized surgical products |  |  |  |  |  |  |
| Non-woven products | 7,024 | 25.4 | 6,593 | 23.5 | 430 | 106.5 |
| Other non-woven products | 1,310 | 4.7 | 914 | 3.3 | 396 | 143.4 |
| Kit products | 16,048 | 57.9 | 17,118 | 61.0 | $\triangle 1,069$ | 93.7 |
| New products | 114 | 0.4 | 129 | 0.5 | $\triangle 15$ | 88.0 |
| Itemized external sales by subsidiary |  |  |  |  |  |  |
| Non-woven products | 414 |  | 190 |  | 223 |  |
| Other non-woven products | 38 |  | - |  | 38 |  |
| Kit products | 0 |  | - |  | 0 |  |
| Others | 51 |  | 63 |  | $\triangle 12$ |  |



Sales Composition by Kit Treatment Category
Fiscal 2018
$(21,829 m i l l i o n)$
In-patient
Anesthetic

Fiscal 2021 Sales Plan by Product Line (Consolidated )

|  | $\neq$ millions, rounded down |  |
| :--- | ---: | ---: |
|  | First Half | Full-year |
| Sterilization products | 1,662 | 3,252 |
| Surgical products | 16,970 | 34,270 |
| Treatment products | 95 | 185 |
| Others | 351 | 692 |
| Total |  | 19,080 |
| Itemized surgical products | 38,400 |  |
| Non-woven products | 4,460 | 8,870 |
| Other non-woven product | 730 | 1,420 |
| Kit products | 11,660 | 23,740 |
| New products | 120 | 240 |
| Itemized external sales by subsidiary |  |  |
| Non-woven products | 320 | 640 |
| Other non-woven product | - | - |
| Kit products | - | - |
| Others | 40 | 80 |


|  |  | $\not \approx$ millions, rounded down |  |
| :--- | ---: | ---: | :---: |
| Change (Amount) | First Half | Full-year |  |
| Sterilization products | 23 | $\triangle 14$ |  |
| Surgical products | 1,323 | 1,929 |  |
| Treatment products | $\triangle 15$ | $\triangle 30$ |  |
| Others | 14 | 11 |  |
| Total | 1,345 | 1,895 |  |


| Itemized surgical products |  |  |
| :--- | ---: | ---: |
| Non-woven products | $\triangle 35$ | $\triangle 413$ |
| Other non-woven products | $\triangle 152$ | $\triangle 260$ |
| Kit products | 1,466 | 2,552 |
| New products | 44 | 49 |
| Itemized external sales by subsidiary |  |  |
| Non-woven products | 70 | 27 |
| Other non-woven products | 3 | 17 |
| Kit products | - | - |
| Others | 3 | 17 |

(\%)

| Net Sales Breakdown | First Half | Full-year |
| :--- | ---: | ---: |
| Sterilization products | 8.7 | 8.5 |
| Surgical products | 88.9 | 89.2 |
| Treatment products | 0.5 | 0.5 |
| Others | 1.8 | 1.8 |
| Total | 100.0 | 100.0 |
| Itemized surgical products |  |  |
| Non-woven products | 23.4 | 23.1 |
| Other non-woven products | 3.8 | 3.7 |
| Kit products |  |  |
| New products | 61.1 | 61.8 |
| Itemized external sales by subsidiary |  |  |
| Non-woven products | 1.7 | 0.6 |
| Other non-woven products | 0.0 | 1.7 |
| Kit products | 0.0 | 0.0 |
| Others | 0.2 | 0.0 |


| Fiscal 2020 Net Sales | $¥$ millions, rounded down |  |
| :---: | :---: | :---: |
|  | First Half | Full-year |
| Sterilization products | 1,639 | 3,266 |
| Surgical products | 15,646 | 32,340 |
| Treatment products | 111 | 215 |
| Others | 337 | 681 |
| Total | 17,734 | 36,504 |
| Itemized surgical products |  |  |
| Non-woven products | 4,495 | 9,283 |
| Other non-woven products | 882 | 1,680 |
| Kit products | 10,193 | 21,187 |
| New products | 75 | 190 |
| Itemized external sales by subsidiary |  |  |
| Non-woven products | 249 | 612 |
| Other non-woven products | 27 | 38 |
| Kit products | 0 | 0 |
| Others | 36 | 62 |
|  |  | (\%) |
| Change (\%) | First Half | Full-year |
| Sterilization products | 101.4 | 99.5 |
| Surgical products | 108.5 | 106.0 |
| Treatment products | 86.1 | 86.0 |
| Others | 104.3 | 101.7 |
| Total | 107.6 | 105.2 |
| Itemized surgical products |  |  |
| Non-woven products | 99.2 | 95.5 |
| Other non-woven products | 82.8 | 84.5 |
| Kit products | 114.4 | 112.0 |
| New products | 159.3 | 126.30 |
| Itemized external sales by subsidiary |  |  |
| Non-woven products | 128.2 | 104.4 |
| Other non-woven products | 109.5 | 128.0 |
| Kit products | 0.0 | 0.0 |
| Others | 0.0 | 0.0 |

SG\&A and Other Income/Expenses (Actual and Forecast, Consolidated)

SG\&A Expenses
$¥$ millions, rounded down

|  | Fiscal 2020 Results | Fiscal 2019 <br> Results | Year-on-Year Comparison | Fiscal 2020 Revised Plan | Revised Plan Comparison | $\begin{gathered} \text { Fiscal } 2021 \\ \text { Plan } \end{gathered}$ | Year-on-Year Comparison |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Packaging and transportation | 1,075 | 1,064 | 11 | 1,080 | $\triangle 4$ | 1,092 | 16 |
| Losses on doubtful accounts | - | - | - | - |  |  |  |
| Samples | 355 | 490 | $\triangle 135$ | 385 | $\triangle 29$ | 442 | 86 |
| Advertising | 47 | 78 | $\triangle 30$ | 54 | $\triangle 6$ | 76 | 28 |
| Personnel | 4,050 | 3,860 | 189 | 4,096 | $\triangle 45$ | 4,358 | 308 |
| Travel | 391 | 611 | $\triangle 219$ | 413 | $\triangle 21$ | 531 | 139 |
| Communication | 138 | 135 | 2 | 134 | 4 | 149 | 11 |
| Consumables | 82 | 129 | $\triangle 46$ | 97 | $\triangle 14$ | 73 | $\triangle 9$ |
| Taxes and public charges | 338 | 343 | $\triangle 4$ | 339 | $\triangle 0$ | 331 | $\triangle 7$ |
| Depreciation | 906 | 1,070 | $\triangle 164$ | 930 | $\triangle 23$ | 900 | $\triangle 6$ |
| Testing and research | 648 | 582 | 65 | 520 | 128 | 501 | $\triangle 146$ |
| Land and housing rent | 435 | 434 | 1 | 445 | $\triangle 9$ | 442 | 7 |
| Miscellaneous | 549 | 594 | $\triangle 44$ | 617 | $\triangle 67$ | 421 | $\triangle 128$ |
| Others | 673 | 730 | $\triangle 57$ | 700 | $\triangle 26$ | 747 | 74 |
| Total | 9,694 | 10,126 | $\triangle 432$ | 9,810 | $\triangle 115$ | 10,070 | 375 |

Other Income/Expenses

|  | Fiscal 2020 Results | Fiscal 2019 <br> Results | Year-on-Year Comparison | Fiscal 2020 Revised Plan | Revised Plan Comparison | Fiscal 2021 Plan | Year-on-Year Comparison |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Interest received | 63 | 70 | $\triangle 6$ | 80 | $\triangle 16$ | 61 | $\triangle 2$ |
| Interest on negotiable securities | - | - | - | - | - |  |  |
| Dividend received | 60 | 70 | $\triangle 10$ | 59 | 1 | 41 | $\triangle 19$ |
| (Totalfinancial earnings) | 124 | 141 | $\triangle 16$ | 139 | $\triangle 14$ | 102 | $\triangle 22$ |
| Foreign exchange gain | 10 | 36 | $\triangle 26$ | 25 | $\triangle 14$ | - | $\triangle 10$ |
| Miscellaneous income | 287 | 327 | $\triangle 40$ | 296 | $\triangle 8$ | 247 | $\triangle 39$ |
| Total Other income | 421 | 505 | $\triangle 83$ | 460 | $\triangle 38$ | 350 | $\triangle 71$ |
| Paid interest | 2 | 1 | 1 | - | 2 | 10 | 8 |
| (Total financial expenses) | 2 | 1 | 1 | - | 2 | 10 | 8 |
| Foreign exchange loss | - | - | - | - | - | - | - |
| Miscellaneous losses | 63 | 21 | 42 | 20 | 43 | 69 | 5 |
| Total non-operating expenses | 65 | 22 | 43 | 20 | 45 | 80 | 14 |

## Capital Expenditures and Depreciation Expenses (Actual and Forecast, Consolidated)

## Capital Expenditures

|  | Capital <br> Expenditures | Year-on-Year <br> Comparison |
| :--- | ---: | ---: |
| Fiscal 2009 | 3,717 | 128.5 |
| Fiscal 2010 | 4,311 | 116.0 |
| Fiscal 2011 | 1,637 | 38.0 |
| Fiscal 2012 | 1,915 | 117.0 |
| Fiscal 2013 | 7,174 | 374.6 |
| Fiscal 2014 | 15,082 | 210.2 |
| Fiscal 2015 | 9,080 | 60.2 |
| Fiscal 2016 | 6,649 | 73.2 |
| Fiscal 2017 | 2,142 | 32.2 |
| Fiscal 2018 | 3,364 | 157.0 |
| Fiscal 2019 | 10,904 | 324.1 |
| Fiscal 2020 | 5,261 | 48.2 |
| Fiscal 2021 | 3,700 | 70.3 |

Depreciation Expenses $\quad \neq$ millions, rounded down,(\%)

|  | SG\&A Expenses | Year-on-Year <br> Comparison | Manufacturing <br> Costs | Year-on-Year <br> Comparison | Total <br> Depreciation <br> Expenses | Year-on-Year <br> Comparison |
| :--- | ---: | ---: | ---: | ---: | ---: | ---: |
| Fiscal 2009 | 715 | 96.1 | 1,842 | 84.0 | 2,557 | 87.1 |
| Fiscal 2010 | 642 | 89.8 | 1,634 | 88.7 | 2,277 | 89.0 |
| Fiscal 2011 | 724 | 112.8 | 2,340 | 143.2 | 3,064 | 134.6 |
| Fiscal 2012 | 844 | 116.6 | 2,127 | 90.9 | 2,971 | 97.0 |
| Fiscal 2013 | 922 | 109.2 | 1,942 | 91.3 | 2,865 | 96.4 |
| Fiscal 2014 | 951 | 103.1 | 1,757 | 90.5 | 2,708 | 94.5 |
| Fiscal 2015 | 1,044 | 109.8 | 2,331 | 132.7 | 3,376 | 124.7 |
| Fiscal 2016 | 1,007 | 96.5 | 3,402 | 145.9 | 4,409 | 130.6 |
| Fiscal 2017 | 914 | 90.8 | 5,320 | 156.4 | 6,235 | 141.4 |
| Fiscal 2018 | 998 | 109.2 | 4,632 | 87.1 | 5,631 | 90.3 |
| Fiscal 2019 | 1,070 | 107.2 | 4,212 | 90.9 | 5,283 | 93.8 |
| Fiscal 2020 | 906 | 84.7 | 3,643 | 86.5 | 4,549 | 86.1 |
| Fiscal 2021 | 900 | 99.3 | 3,600 | 98.8 | 4,500 | 98.9 |

Note: Figures for Fiscal 2021 are Company forecasts

[^0]
## Balance Sheets (Major Changes)/Statements of Cash Flows (Consolidated)

## Major Changes on Balance Sheets

$¥$ millions, rounded down

|  | Balance at March 31, 2021 | Change |  | Balance at March 31, 2021 | Change |
| :---: | :---: | :---: | :---: | :---: | :---: |
| Current assets | 41,322 | $\triangle 1,906$ | Current liabilities | 7,590 | $\triangle 2,770$ |
| Cash and bank deposits | 20,549 | $\triangle 2,827$ | Notes and accounts payable | 4,615 | $\triangle 60$ |
| Notes and accounts receivable | 11,390 | 38 | Accrued expenses | 363 | $\triangle 2,211$ |
| Short-term investments | - | - | Long-term loans due within 1 year | 64 | 64 |
| Inventories | 8,805 | 937 | Income taxes | 1,107 | 46 |
| Others | 576 | $\triangle 55$ | Allowance for employees' bonuses | 520 | 54 |
|  |  |  | Payable notes for equipment | 266 | $\triangle 306$ |
|  |  |  | Reserve for disaster loss | - |  |
|  |  |  | Others | 651 | $\triangle 358$ |
| Fixed assets | 64,322 | 887 | Long-term liabilities | 2,102 | $\triangle 279$ |
| Property, plant and equipment | 52,794 | 943 | Long-term borrowings | - | $\triangle 175$ |
| Buildings and structures | 22,333 | $\triangle 840$ | Others | 2,102 | $\triangle 103$ |
| Machinery, equipment and vehicles | 7,167 | $\triangle 1,597$ | Total liabilities | 9,692 | $\triangle 3,050$ |
| Land | 9,580 | $\triangle 23$ | Total net assets | 95,951 | 2,030 |
| Construction in progress | 12,697 | 3,702 | Common stock | 7,123 |  |
| Others | 1,015 | $\triangle 296$ | Capital surplus | 8,336 |  |
| Intangibles | 1,951 | $\triangle 348$ | Retained earnings | 86,149 | 2,914 |
| Investments and others | 9,576 | 292 | Treasury stock | $\triangle 8,902$ | $\triangle 344$ |
| Investments securities | 7,987 | 46 | Others | 3,245 | $\triangle 539$ |
| Others | 1,588 | 246 |  |  |  |
| Total assets | 105,644 | $\triangle 1,019$ | Total liabilities and shareholders' equity | 105,644 | $\triangle 1,019$ |

* Comparison with the end of previous fiscal year:

Equity ratio decreased from $\mathbf{8 8 . 0 \%}$ at the end of the previous fiscal year to $\mathbf{9 0 . 8 \%}$

| Statements of Cash Flows | $¥$ millions, rounded down |  |  |
| :---: | :---: | :---: | :---: |
| I Operating activities | 6,864 | Income before income taxes | 6,989 |
|  |  | Depreciation | 4,549 |
|  |  | Gain on sales of investment securities | $\triangle 1,028$ |
|  |  | Income taxes paid | $\triangle 2,025$ |
| II Investing activities | $\triangle$ 6,950 | Proceeds from sales of investment securities Purchase of tangible fixed assets | $\begin{array}{r} \hline \triangle 7,350 \\ 1,409 \end{array}$ |
| III Financing activities | $\triangle 2,500$ | Cash devidends paid | $\triangle 2,044$ |
| IV Effect of exchange rate changes | $\triangle 150$ |  |  |
| Net changes in cash and cash equivalents | $\triangle 2,746$ |  |  |

Fiscal 2020 Statements of Income (Non-Consolidated)

| First Quarter Results |  |  |  |  | $¥$ millions, rounded down |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | June 2020First Quarter Results |  | June 2019 <br> First Quarter Results |  | Year-on-Year Comparison |  |
|  | Amount | \% of total | Amount | \% of total | Amount | \% |
| Net sales | 8,292 | 100.0 | 8,964 | 100.0 | $\triangle 672$ | 92.5 |
| Cost of Sales | 4,965 | 59.9 | 5,400 | 60.2 | $\triangle 434$ | 91.9 |
| Gross profit | 3,327 | 40.1 | 3,564 | 39.8 | $\triangle 237$ | 93.3 |
| SG\&A expenses | 2,300 | 27.7 | 2,404 | 26.8 | $\triangle 104$ | 95.7 |
| Operating income | 1,026 | 12.4 | 1,159 | 12.9 | $\triangle 133$ | 88.5 |
| Other income | 51 |  | 64 |  | $\triangle 12$ |  |
| Other expenses | 7 |  | 9 |  | $\triangle 2$ |  |
| Ordinary income | 1,071 | 12.9 | 1,214 | 13.5 | $\triangle 143$ | 88.2 |
| Extraordinary income | - |  |  |  | - |  |
| Extraordinary expenses | - |  | 0 |  | $\triangle 0$ |  |
| Income before income taxes | 1,071 | 12.9 | 1,214 | 13.5 | $\triangle 143$ | 88.2 |
| Corporation tax,inhabitants taxes, etc. | 307 |  | 370 |  | $\triangle 63$ |  |
| (Tax burden) | 28.7\% |  | 30.5\% |  |  |  |
| Net income | 764 | 9.2 | 843 | 9.4 | $\triangle 79$ | 90.5 |
| EPS (total shares) | ¥23.38 |  | ¥25.82 |  |  |  |
| EPS (minus treasury shares) | $¥ 25.28$ |  | $¥ 27.95$ |  |  |  |
| Number of shares outstanding | 32,682,310 |  | 32,682,310 |  |  |  |
| Average number of shares outstanding (after deducting treasury shares) | 30,223,453 |  | 30,191,789 |  |  |  |

## First Half Results $¥$ millions, rounded down

|  | Sept. 2020 <br> Interim Results |  | Sept. 2019 <br> Interim Results |  | Year-on-Year Comparison |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | Amount | \% of total | Amount | \% of total | Amount | \% |
| Net sales | 17,442 | 100.0 | 18,223 | 100.0 | $\triangle 780$ | 95.7 |
| Cost of Sales | 10,479 | 60.1 | 11,061 | 60.7 | $\triangle 581$ | 94.7 |
| Gross profit | 6,963 | 39.9 | 7,161 | 39.3 | $\triangle 198$ | 97.2 |
| SG\&A expenses | 4,581 | 26.3 | 4,861 | 26.7 | $\triangle 279$ | 94.2 |
| Operating income | 2,381 | 13.7 | 2,300 | 12.6 | 81 | 103.5 |
| Other income | 92 |  | 119 |  | $\triangle 26$ |  |
| Other expenses | 14 |  | 15 |  | $\triangle 1$ |  |
| Ordinary income | 2,459 | 14.1 | 2,403 | 13.2 | 56 | 102.3 |
| Extraordinary income | 1,028 |  | 1,942 |  | $\triangle 913$ |  |
| Extraordinary expenses | 1 |  | 1 |  | $\triangle 0$ |  |
| Income before income taxes | 3,486 | 20.0 | 4,343 | 23.8 | $\triangle 856$ | 80.3 |
| Corporation tax,inhabitants taxes, etc. | 1,000 |  | 1,325 |  | $\triangle 325$ |  |
| (Tax burden) | 28.7\% |  | 30.5\% |  |  |  |
| Net income | 2,486 | 14.3 | 3,018 | 16.6 | $\triangle 531$ | 82.4 |
| EPS (total shares) | ¥76.08 |  | ¥92.34 |  |  |  |
| EPS (minus treasury shares) | ¥82.25 |  | $¥ 99.95$ |  |  |  |
| Number of shares outstanding | 32,682,310 |  | 32,682,310 |  |  |  |
| Average number of shares outstanding (after deducting treasury shares) | 30,228,126 |  | 30,196,594 |  |  |  |
| Third Quarter Results (Cumulative) |  |  |  | $¥$ | illions, roun | down |


|  | Dec. 2020 <br> Third Quarter Results |  | Dec. 2019Third Quarter Results |  | Year-on-Year Comparison |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | Amount | \% of total | Amount | \% of total | Amount | \% |
| Net sales | 27,214 | 100.0 | 27,816 | 100.0 | $\triangle 601$ | 97.8 |
| Cost of Sales | 16,213 | 59.6 | 16,781 | 60.3 | $\triangle 568$ | 96.6 |
| Gross profit | 11,001 | 40.4 | 11,034 | 39.7 | $\triangle 33$ | 99.7 |
| SG\&A expenses | 6,954 | 25.6 | 7,344 | 26.4 | $\triangle 389$ | 94.7 |
| Operating income | 4,046 | 14.9 | 3,689 | 13.3 | 356 | 109.7 |
| Other income | 354 |  | 400 |  | $\triangle 45$ |  |
| Other expenses | 22 |  | 25 |  | $\triangle 2$ |  |
| Ordinary income | 4,378 | 16.1 | 4,065 | 14.6 | 313 | 107.7 |
| Extraordinary income | 1,028 |  | 1,942 |  | $\triangle 913$ |  |
| Extraordinary expenses | 3 |  | 1 |  | 1 |  |
| Income before income taxes | 5,404 | 19.9 | 6,005 | 21.6 | $\triangle 601$ | 90.0 |
| Corporation tax,inhabitants taxes, etc. | 1,550 |  | 1,832 |  | $\triangle 282$ |  |
| (Tax burden) | 28.7\% |  | 30.5\% |  |  |  |
| Net income | 3,853 | 14.2 | 4,172 | 15.0 | $\triangle 318$ | 92.4 |
| EPS (total shares) | ¥117.92 |  | ¥127.67 |  |  |  |
| EPS (minus treasury shares) | $¥ 127.48$ |  | $¥ 138.17$ |  |  |  |
| Number of shares outstanding | 32,682,310 |  | 32,682,310 |  |  |  |
| Average number of shares outstanding (after deducting treasury shares) | 30,232,009 |  | 30,200,684 |  |  |  |

## Full-year Results

$¥$ millions, rounded down


## Fiscal 2020 Statements of Income Half (Non-Consolidated)

|  | First Quarter | Second Quarter | Third Quarter | Fourth Quarter |
| :---: | :---: | :---: | :---: | :---: |
| Net sales | 8,292 | 9,150 | 9,771 | 8,598 |
| Cost of Sales | 4,965 | 5,513 | 5,733 | 5,100 |
| Gross profit | 3,327 | 3,636 | 4,037 | 3,498 |
| SG\&A expenses | 2,300 | 2,281 | 2,372 | 2,500 |
| Operating income | 1,026 | 1,354 | 1,664 | 997 |
| Other income | 51 | 40 | 262 | 211 |
| Other expenses | 7 | 7 | 8 | 64 |
| Ordinary income | 1,071 | 1,387 | 1,919 | 1,144 |
| Extraordinary income |  | 1,028 |  |  |
| Extraordinary expenses |  | 1 | 1 | 25 |
| Income before income taxes | 1,071 | 2,415 | 1,917 | 1,118 |
| Corporation tax, inhabitants taxes, etc. | 307 | 692 | 550 | 302 |
| (Tax burden) | 28.7\% | 28.7\% | 28.7\% | 27.1\% |
| Net income | 764 | 1,722 | 1,367 | 815 |


| First Half | Third Quarter (Cumulative) | Full-year |
| :---: | :---: | :---: |
| 17,442 | 27,214 | 35,813 |
| 10,479 | 16,213 | 21,313 |
| 6,963 | 11,001 | 14,499 |
| 4,581 | 6,954 | 9,455 |
| 2,381 | 4,046 | 5,043 |
| 92 | 354 | 566 |
| 14 | 22 | 87 |
| 2,459 | 4,378 | 5,522 |
| 1,028 | 1,028 | 1,028 |
| 1 | 3 | 28 |
| 3,486 | 5,404 | 6,522 |
| 1,000 | 1,550 | 1,853 |
| 28.7\% | 28.7\% | 28.4\% |
| 2,486 | 3,853 | 4,669 |

Fiscal 2019 Results

|  | First Quarter | Second Quarter | Third Quarter | Fourth Quarter |
| :---: | :---: | :---: | :---: | :---: |
| Net sales | 8,964 | 9,258 | 9,593 | 9,063 |
| Cost of Sales | 5,400 | 5,661 | 5,720 | 5,433 |
| Gross profit | 3,564 | 3,597 | 3,872 | 3,630 |
| SG\&A expenses | 2,404 | 2,456 | 2,482 | 2,511 |
| Operating income | 1,159 | 1,140 | 1,389 | 1,118 |
| Other income | 64 | 54 | 281 | 270 |
| Other expenses | 9 | 6 | 9 | 17 |
| Ordinary income | 1,214 | 1,188 | 1,661 | 1,371 |
| Extraordinary income |  | 1,942 |  |  |
| Extraordinary expenses | 0 | 1 | 0 | 7 |
| Income before income taxes | 1,214 | 3,129 | 1,661 | 1,364 |
| Corporation tax, inhabitants taxes, etc. | 370 | 955 | 507 | 281 |
| (Tax burden) | 30.5\% | 30.5\% | 30.5\% | 20.6\% |
| Net income | 843 | 2,174 | 1,154 | 1,083 |


| First Half | Third Quarter (Cumulative) | Full-year |
| :---: | :---: | :---: |
| 18,223 | 27,816 | 36,879 |
| 11,061 | 16,781 | 22,214 |
| 7,161 | 11,034 | 14,664 |
| 4,861 | 7,344 | 9,855 |
| 2,300 | 3,689 | 4,808 |
| 119 | 400 | 670 |
| 15 | 25 | 42 |
| 2,403 | 4,065 | 5,436 |
| 1,942 | 1,942 | 1,942 |
| 1 | 1 | 9 |
| 4,343 | 6,005 | 7,369 |
| 1,325 | 1,832 | 2,114 |
| 30.5\% | 30.5\% | 28.7\% |
| 3,018 | 4,172 | 5,255 |


|  | First Quarter | Second Quarter | Third Quarter | Fourth Quarter |
| :---: | :---: | :---: | :---: | :---: |
| Net sales | $\triangle 672$ | $\triangle 108$ | 178 | $\triangle 464$ |
| Cost of Sales | $\triangle 434$ | $\triangle 147$ | 13 | $\triangle 332$ |
| Gross profit | $\triangle 237$ | 39 | 164 | $\triangle 132$ |
| SG\&A expenses | $\triangle 104$ | $\triangle 175$ | $\triangle 110$ | $\triangle 10$ |
| Operating income | $\triangle 133$ | 214 | 274 | $\triangle 121$ |
| Other income | $\triangle 12$ | $\triangle 14$ | $\triangle 19$ | $\triangle 58$ |
| Other expenses | $\triangle 2$ | 1 | $\triangle 1$ | 47 |
| Ordinary income | $\triangle 143$ | 199 | 257 | $\triangle 227$ |
| Extraordinary income |  | $\triangle 913$ |  |  |
| Extraordinary expenses | $\triangle 0$ | $\triangle 0$ | 1 | 18 |
| Income before income taxes | $\triangle 143$ | $\triangle 713$ | 255 | $\triangle 245$ |
| Corporation tax, inhabitants taxes, etc. | $\triangle 63$ | $\triangle 262$ | 42 | 21 |
| (Tax burden) |  |  |  |  |
| Net income | $\triangle 79$ | $\triangle 451$ | 212 | $\triangle 267$ |


| First Half | Third Quarter (Cumulative) | Full-year |
| :---: | :---: | :---: |
| $\triangle 780$ | $\triangle 601$ | $\triangle 1,066$ |
| $\triangle 581$ | $\triangle 568$ | $\triangle 901$ |
| $\triangle 198$ | $\triangle 33$ | $\triangle 165$ |
| $\triangle 279$ | $\triangle 389$ | $\triangle 400$ |
| 81 | 356 | 234 |
| $\triangle 26$ | $\triangle 45$ | $\triangle 104$ |
| $\triangle 1$ | $\triangle 2$ | 44 |
| 56 | 313 | 85 |
| $\triangle 913$ | $\triangle 913$ | $\triangle 913$ |
| $\triangle 0$ | 1 | 19 |
| $\triangle 856$ | $\triangle 601$ | $\triangle 847$ |
| $\triangle 325$ | $\triangle 282$ | $\triangle 260$ |
|  |  |  |
| $\triangle 531$ | $\triangle 318$ | $\triangle 586$ |

Change(\%)

|  | First Quarter | Second Quarter | Third Quarter | Fourth Quarter |
| :---: | :---: | :---: | :---: | :---: |
| Net sales | 92.5 | 98.8 | 101.9 | 94.9 |
| Cost of Sales | 91.9 | 97.4 | 100.2 | 93.9 |
| Gross profit | 93.3 | 101.1 | 104.3 | 96.4 |
| SG\&A expenses | 95.7 | 92.9 | 95.6 | 99.6 |
| Operating income | 88.5 | 118.8 | 119.8 | 89.1 |
| Other income |  |  |  |  |
| Other expenses |  |  |  |  |
| Ordinary income | 88.2 | 116.8 | 115.5 | 83.4 |
| Extraordinary income |  |  |  |  |
| Extraordinary expenses |  |  |  |  |
| Income before income taxes | 88.2 | 77.2 | 115.4 | 82.0 |
| Corporation tax, inhabitants taxes, etc. |  |  |  |  |
| (Tax burden) |  |  |  |  |
| Net income | 90.5 | 79.2 | 118.4 | 75.3 |


| First Half | Third Quarter <br> (Cumulative) | Full-year |
| ---: | ---: | ---: |
| 95.7 | 97.8 | 97.1 |
| 94.7 | 96.6 | 95.9 |
| 97.2 | 99.7 | 98.9 |
| 94.2 | 94.7 | 95.9 |
| 103.5 | 109.7 | 104.9 |
|  |  |  |
| 102.3 | 107.7 | 101.6 |
|  |  |  |
| 80.3 | 90.0 | 88.5 |
|  |  |  |
|  |  |  |
| 82.4 | 92.4 | 88.8 |

## Fiscal 2020 Breakdown

|  | First Quarter | Second Quarter | Third Quarter | Fourth Quarter |
| :---: | :---: | :---: | :---: | :---: |
| Net sales | 100.0 | 100.0 | 100.0 | 100.0 |
| Cost of Sales | 59.9 | 60.3 | 58.7 | 59.3 |
| Gross profit | 40.1 | 39.7 | 41.3 | 40.7 |
| SG\&A expenses | 27.7 | 24.9 | 24.3 | 29.1 |
| Operating income | 12.4 | 14.8 | 17.0 | 11.6 |
| Other income |  |  |  |  |
| Other expenses |  |  |  |  |
| Ordinary income | 12.9 | 15.2 | 19.6 | 13.3 |
| Extraordinary income |  |  |  |  |
| Extraordinary expenses |  |  |  |  |
| Income before income taxes | 12.9 | 26.4 | 19.6 | 13.0 |
| Corporation tax, inhabitants taxes, etc. |  |  |  |  |
| (Tax burden) |  |  |  |  |
| Net income | 9.2 | 18.8 | 14.0 | 9.5 |


| First Half | Third Quarter <br> (Cumulative) | Full-year |
| ---: | ---: | ---: |
| 100.0 | 100.0 | 100.0 |
| 60.1 | 59.6 | 59.5 |
| 39.9 | 40.4 | 40.5 |
| 26.3 | 25.6 | 26.4 |
| 13.7 | 14.9 | 14.1 |
|  |  |  |
| 14.1 | 16.1 | 15.4 |
|  |  |  |
|  |  |  |
| 20.0 | 19.9 | 18.2 |
|  |  |  |
|  |  |  |
| 14.3 | 14.2 | 13.0 |

Fiscal 2021 Projected Statements of Income (Non-Consolidated)

| Cumulative | $¥$ millions, rounded down,(\%) |  |  |  |
| :---: | :---: | :---: | :---: | :---: |
|  | First Half | \% of total | Full-year | \% of total |
| Net sales | 18,720 | 100.0 | 37,680 | 100.0 |
| Operating income | 2,940 | 15.7 | 5,790 | 15.4 |
| Ordinary income | 2,920 | 15.6 | 6,200 | 16.5 |
| Net income | 2,090 | 11.2 | 4,440 | 11.8 |
| EPS (before deducting treasury shares) | $¥ \square 3.95$ |  | 7135.85 |  |
| EPS (minus treasury shares) | $¥ 69.38$ |  | $¥ 147.40$ |  |
| Number of shares outstanding 32,682,310 |  |  |  |  |
| Shares outstanding at FY2020 year-end 30,122,328(deducting treasury shares) |  |  |  |  |
|  |  |  |  |  |

Fiscal 2020 Results

| Net sales | 17,442 | 100.0 | 35,813 | 100.0 |
| :--- | ---: | ---: | ---: | ---: |
| Operating income | 2,381 | 13.7 | 5,043 | 14.1 |
| Ordinary income | 2,459 | 14.1 | 5,522 | 15.4 |
| Net income | 2,486 | 14.3 | 4,669 | 13.0 |

Change (Amount and \%)

| Net sales | 1,277 | 107.3 | 1,866 | 105.2 |
| :--- | ---: | ---: | ---: | ---: |
| Operating income | 558 | 123.4 | 746 | 114.8 |
| Ordinary income | 460 | 118.7 | 677 | 112.3 |
| Net income | $\triangle 396$ | 84.1 | $\triangle 229$ | 95.1 |

Total Manufacturing Costs (Non-Consolidated)
$¥$ millions, rounded down

|  | FY 2011 | FY 2012 | FY2013 | FY2014 | FY2015 | FY2016 | FY2017 | FY 2018 | FY2019 | FY2020 | Plan FY2021 |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Materials | 9,712 | 10,295 | 10,821 | 11,728 | 12,545 | 12,945 | 12,803 | 12,769 | 12,765 | 12,883 | 12,914 |
| Personnel | 1,780 | 1,761 | 1,882 | 1,797 | 1,795 | 1,742 | 1,713 | 1,661 | 1,658 | 1,750 | 1,761 |
| Outsourcing | 368 | 367 | 414 | 389 | 406 | 411 | 398 | 412 | 369 | 390 | 372 |
| Depreciation expenses | 2,102 | 1,868 | 1,603 | 1,370 | 1,969 | 3,081 | 5,035 | 4,392 | 3,974 | 3,385 | 3,270 |
| Others | 1,466 | 1,460 | 1,512 | 1,492 | 1,466 | 1,755 | 1,910 | 2,209 | 2,139 | 2,116 | 2,023 |
| Total | 15,430 | 15,752 | 16,234 | 16,779 | 18,183 | 19,935 | 21,861 | 21,445 | 20,907 | 20,527 | 20,342 |

Increase Rate
(\%)

|  | FY 2011 | FY 2012 | FY2013 | FY2014 | FY2015 | FY2016 | FY2017 | FY 2018 | FY2019 | FY2020 |
| :--- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Plan FY2021 |  |  |  |  |  |  |  |  |  |  |
| Materials | 106.8 | 106.0 | 105.1 | 108.4 | 107.0 | 103.2 | 98.9 | 99.7 | 100.0 | 100.9 |
| Personnel | 103.9 | 98.9 | 106.9 | 95.5 | 99.9 | 97.1 | 98.3 | 97.0 | 99.8 | 105.6 |
| Outsourcing | 110.3 | 99.7 | 112.9 | 93.9 | 104.4 | 101.1 | 96.9 | 103.4 | 89.6 | 105.8 |
| Depreciation expenses | 151.3 | 88.9 | 85.8 | 85.5 | 143.7 | 156.4 | 163.4 | 87.2 | 90.5 | 85.2 |
| Others | 119.6 | 99.6 | 103.5 | 98.7 | 98.2 | 119.7 | 108.9 | 115.6 | 96.8 | 98.9 |
| Total | 112.2 | 102.1 | 103.1 | 103.4 | 108.4 | 109.6 | 109.7 | 98.1 | 97.5 | 98.2 |

## Composition Rate

|  | FY 2011 | FY 2012 | FY2013 | FY2014 | FY2015 | FY2016 | FY2017 | FY 2018 | FY2019 | FY2020 | Plan FY2021 |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Materials | 62.9 | 65.4 | 66.7 | 69.9 | 69.0 | 64.9 | 58.6 | 59.5 | 61.1 | 62.8 | 63.5 |
| Personnel | 11.5 | 11.2 | 11.6 | 10.7 | 9.9 | 8.7 | 7.8 | 7.7 | 7.9 | 8.5 | 8.7 |
| Outsourcing | 2.4 | 2.3 | 2.6 | 2.3 | 2.2 | 2.1 | 1.8 | 1.9 | 1.8 | 1.9 | 1.8 |
| Depreciation expenses | 13.6 | 11.9 | 9.9 | 8.2 | 10.8 | 15.5 | 23.0 | 20.5 | 19.0 | 16.5 | 16.1 |
| Others | 9.5 | 9.3 | 9.3 | 8.9 | 8.1 | 8.8 | 8.7 | 10.3 | 10.2 | 10.3 | 9.9 |
| Total | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 |

$¥$ million
25,000
Total Manufacturing Costs




[^0]:    Fiscal 2005 Operamaster expansion line : 1,469, New distribution center : 1,947
    Fiscal 2006 New distribution center : 886
    Fiscal 2007 Industrial-use land : 973
    Fiscal 2008 Industrial-use land : 752, Sterilization equipment : 876 ,Indonesia factory : 381
    Fiscal 2009 Sterilization equipment : 1,833,Indonesia factory : 995
    Fiscal 2010 Sterilization equipment : 2,732
    Fiscal 2013 New plant construction costs : 5,166
    Fiscal 2014 New plant construction costs : 8,113, New plant equipment costs : 4,567
    Fiscal 2015 New plant : 7,300
    Fiscal 2016 New plant : 5,981
    Fiscal 2019 New plant additional investment : 9,512
    Fiscal 2020 New plant additional investment : 3,644

